Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients

Accurate diagnosis of plasmacytoid urothelial carcinoma (PUC) is important given its poor prognosis and frequent presentation at high stage. We aim to assess the clinicopathological features, molecular aberrations, and follow-up data in a series of PUC cases from a single tertiary cancer center. Sev...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human pathology 2019-08, Vol.90, p.27-36
Hauptverfasser: Perrino, Carmen M., Eble, John, Kao, Chia-Sui, Whaley, Rumeal D., Cheng, Liang, Idrees, Mohammad, Hashemi-Sadraei, Neda, Monn, M. Francesa, Kaimakliotis, Hristos Z., Bandali, Elhaam, Grignon, David
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 36
container_issue
container_start_page 27
container_title Human pathology
container_volume 90
creator Perrino, Carmen M.
Eble, John
Kao, Chia-Sui
Whaley, Rumeal D.
Cheng, Liang
Idrees, Mohammad
Hashemi-Sadraei, Neda
Monn, M. Francesa
Kaimakliotis, Hristos Z.
Bandali, Elhaam
Grignon, David
description Accurate diagnosis of plasmacytoid urothelial carcinoma (PUC) is important given its poor prognosis and frequent presentation at high stage. We aim to assess the clinicopathological features, molecular aberrations, and follow-up data in a series of PUC cases from a single tertiary cancer center. Seventy-two urinary bladder, ureteral, and renal pelvic specimens with urothelial carcinoma with plasmacytoid differentiation were identified. Immunohistochemical stains were performed on 48 cases. Among urinary bladder origin markers, GATA3 was most sensitive (96%). Breast carcinoma markers (estrogen receptor, mammaglobin) were usually negative, but progesterone receptor stained 1 case (4%). Neuroendocrine markers CD56 and TTF-1 were each positive in 1 case (4% and 4%, respectively). Gastrointestinal adenocarcinoma marker CDX2 was positive in 4 cases (15%), but nuclear β-catenin was negative in all cases. CD138 was positive in 83% and E-cadherin expression was lost in 57% of cases. Fluorescence in situ hybridization using the UroVysion Bladder Cancer Kit and FGFR3 mutational analysis using polymerase chain reaction were performed on 15 cases; deletion of chromosome 9p21 was common (60%), and FGFR3 mutations were detected in 60% of cases (5 cases had both deletion 9p21 and FGFR3 mutations). Cases were divided into 3 morphologic groups: classic (29%), desmoplastic (35%), and pleomorphic (36%). The 3 morphologic subtypes had distinct survival outcomes (P = .083), with median survival for all patients 18 being months versus 10 months for the desmoplastic group. •Urothelial carcinoma with plasmacytoid differentiation can be divided into 3 morphologic categories: (1) classic, (2) pleomorphic, and (3) desmoplastic.•Cases with plasmacytoid differentiation often present at a high stage, and within our dataset, cases assigned to the desmoplastic group had a worse outcome.•Urinary bladder origin immunohistochemical stains are sensitive for detecting the plasmacytoid variant.•Molecular aberrations present in conventional urothelial carcinoma are also present in the plasmacytoid variant.
doi_str_mv 10.1016/j.humpath.2019.04.012
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2232111605</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0046817719300772</els_id><sourcerecordid>2262664522</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-e1353133ff7c3d0ad1aa480849628bbe1ca578bc13c7cbb00f9bd2f00d91d1833</originalsourceid><addsrcrecordid>eNqFkT2P1DAQhi0E4paFnwCyREOT3Iwd54MGoRMcSCdBAbXl2A7xKokXf5y0_x6fdqGguWqa531nNA8hrxFqBGyvD_Wc16NKc80AhxqaGpA9ITsUnFU9H9hTsgNo2qrHrrsiL2I8ACCKRjwnVxxBNP3Q7cj990XFVelT8s5cGzdNOVqag0-zXZxaqFZBu82v6j1VNLrt12Irt8XkUk7Ob9Sta9787GLyerar0yWjNkNXv1idFxVoTNmcqJ9oO9BysLNbii_Js0kt0b66zD35-fnTj5sv1d232683H-8qLaBNlUUuOHI-TZ3mBpRBpZoe-mZoWT-OFrUSXT9q5LrT4wgwDaNhE4AZ0GDP-Z68O_ceg_-dbUxydVHbZVGb9TlKxjhDxBZEQd_-hx58Dlu5rlAta9tGFHpPxJnSwccY7CSPwa0qnCSCfBAjD_IiRj6IkdDIIqbk3lza87ha8y_110QBPpwBW95x72yQUZdXaWtcsDpJ490jK_4AC86jzQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2262664522</pqid></control><display><type>article</type><title>Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients</title><source>MEDLINE</source><source>ScienceDirect Freedom Collection (Elsevier)</source><creator>Perrino, Carmen M. ; Eble, John ; Kao, Chia-Sui ; Whaley, Rumeal D. ; Cheng, Liang ; Idrees, Mohammad ; Hashemi-Sadraei, Neda ; Monn, M. Francesa ; Kaimakliotis, Hristos Z. ; Bandali, Elhaam ; Grignon, David</creator><creatorcontrib>Perrino, Carmen M. ; Eble, John ; Kao, Chia-Sui ; Whaley, Rumeal D. ; Cheng, Liang ; Idrees, Mohammad ; Hashemi-Sadraei, Neda ; Monn, M. Francesa ; Kaimakliotis, Hristos Z. ; Bandali, Elhaam ; Grignon, David</creatorcontrib><description>Accurate diagnosis of plasmacytoid urothelial carcinoma (PUC) is important given its poor prognosis and frequent presentation at high stage. We aim to assess the clinicopathological features, molecular aberrations, and follow-up data in a series of PUC cases from a single tertiary cancer center. Seventy-two urinary bladder, ureteral, and renal pelvic specimens with urothelial carcinoma with plasmacytoid differentiation were identified. Immunohistochemical stains were performed on 48 cases. Among urinary bladder origin markers, GATA3 was most sensitive (96%). Breast carcinoma markers (estrogen receptor, mammaglobin) were usually negative, but progesterone receptor stained 1 case (4%). Neuroendocrine markers CD56 and TTF-1 were each positive in 1 case (4% and 4%, respectively). Gastrointestinal adenocarcinoma marker CDX2 was positive in 4 cases (15%), but nuclear β-catenin was negative in all cases. CD138 was positive in 83% and E-cadherin expression was lost in 57% of cases. Fluorescence in situ hybridization using the UroVysion Bladder Cancer Kit and FGFR3 mutational analysis using polymerase chain reaction were performed on 15 cases; deletion of chromosome 9p21 was common (60%), and FGFR3 mutations were detected in 60% of cases (5 cases had both deletion 9p21 and FGFR3 mutations). Cases were divided into 3 morphologic groups: classic (29%), desmoplastic (35%), and pleomorphic (36%). The 3 morphologic subtypes had distinct survival outcomes (P = .083), with median survival for all patients 18 being months versus 10 months for the desmoplastic group. •Urothelial carcinoma with plasmacytoid differentiation can be divided into 3 morphologic categories: (1) classic, (2) pleomorphic, and (3) desmoplastic.•Cases with plasmacytoid differentiation often present at a high stage, and within our dataset, cases assigned to the desmoplastic group had a worse outcome.•Urinary bladder origin immunohistochemical stains are sensitive for detecting the plasmacytoid variant.•Molecular aberrations present in conventional urothelial carcinoma are also present in the plasmacytoid variant.</description><identifier>ISSN: 0046-8177</identifier><identifier>EISSN: 1532-8392</identifier><identifier>DOI: 10.1016/j.humpath.2019.04.012</identifier><identifier>PMID: 31054897</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - metabolism ; Bladder ; Bladder cancer ; Breast cancer ; Carcinoma, Transitional Cell - diagnosis ; Carcinoma, Transitional Cell - metabolism ; Carcinoma, Transitional Cell - pathology ; Diffuse ; Female ; Humans ; Immunohistochemistry ; Keratin ; Kidney Neoplasms - diagnosis ; Kidney Neoplasms - metabolism ; Kidney Neoplasms - pathology ; Male ; Medical prognosis ; Metastasis ; Middle Aged ; Morphology ; Plasmacytoid ; Retrospective Studies ; Signet ring ; Stains &amp; staining ; Tumors ; Ureteral Neoplasms - diagnosis ; Ureteral Neoplasms - metabolism ; Ureteral Neoplasms - pathology ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - metabolism ; Urinary Bladder Neoplasms - pathology ; Urothelial carcinoma</subject><ispartof>Human pathology, 2019-08, Vol.90, p.27-36</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><rights>2019. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c506t-e1353133ff7c3d0ad1aa480849628bbe1ca578bc13c7cbb00f9bd2f00d91d1833</citedby><cites>FETCH-LOGICAL-c506t-e1353133ff7c3d0ad1aa480849628bbe1ca578bc13c7cbb00f9bd2f00d91d1833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.humpath.2019.04.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31054897$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perrino, Carmen M.</creatorcontrib><creatorcontrib>Eble, John</creatorcontrib><creatorcontrib>Kao, Chia-Sui</creatorcontrib><creatorcontrib>Whaley, Rumeal D.</creatorcontrib><creatorcontrib>Cheng, Liang</creatorcontrib><creatorcontrib>Idrees, Mohammad</creatorcontrib><creatorcontrib>Hashemi-Sadraei, Neda</creatorcontrib><creatorcontrib>Monn, M. Francesa</creatorcontrib><creatorcontrib>Kaimakliotis, Hristos Z.</creatorcontrib><creatorcontrib>Bandali, Elhaam</creatorcontrib><creatorcontrib>Grignon, David</creatorcontrib><title>Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients</title><title>Human pathology</title><addtitle>Hum Pathol</addtitle><description>Accurate diagnosis of plasmacytoid urothelial carcinoma (PUC) is important given its poor prognosis and frequent presentation at high stage. We aim to assess the clinicopathological features, molecular aberrations, and follow-up data in a series of PUC cases from a single tertiary cancer center. Seventy-two urinary bladder, ureteral, and renal pelvic specimens with urothelial carcinoma with plasmacytoid differentiation were identified. Immunohistochemical stains were performed on 48 cases. Among urinary bladder origin markers, GATA3 was most sensitive (96%). Breast carcinoma markers (estrogen receptor, mammaglobin) were usually negative, but progesterone receptor stained 1 case (4%). Neuroendocrine markers CD56 and TTF-1 were each positive in 1 case (4% and 4%, respectively). Gastrointestinal adenocarcinoma marker CDX2 was positive in 4 cases (15%), but nuclear β-catenin was negative in all cases. CD138 was positive in 83% and E-cadherin expression was lost in 57% of cases. Fluorescence in situ hybridization using the UroVysion Bladder Cancer Kit and FGFR3 mutational analysis using polymerase chain reaction were performed on 15 cases; deletion of chromosome 9p21 was common (60%), and FGFR3 mutations were detected in 60% of cases (5 cases had both deletion 9p21 and FGFR3 mutations). Cases were divided into 3 morphologic groups: classic (29%), desmoplastic (35%), and pleomorphic (36%). The 3 morphologic subtypes had distinct survival outcomes (P = .083), with median survival for all patients 18 being months versus 10 months for the desmoplastic group. •Urothelial carcinoma with plasmacytoid differentiation can be divided into 3 morphologic categories: (1) classic, (2) pleomorphic, and (3) desmoplastic.•Cases with plasmacytoid differentiation often present at a high stage, and within our dataset, cases assigned to the desmoplastic group had a worse outcome.•Urinary bladder origin immunohistochemical stains are sensitive for detecting the plasmacytoid variant.•Molecular aberrations present in conventional urothelial carcinoma are also present in the plasmacytoid variant.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Bladder</subject><subject>Bladder cancer</subject><subject>Breast cancer</subject><subject>Carcinoma, Transitional Cell - diagnosis</subject><subject>Carcinoma, Transitional Cell - metabolism</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Diffuse</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Keratin</subject><subject>Kidney Neoplasms - diagnosis</subject><subject>Kidney Neoplasms - metabolism</subject><subject>Kidney Neoplasms - pathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Morphology</subject><subject>Plasmacytoid</subject><subject>Retrospective Studies</subject><subject>Signet ring</subject><subject>Stains &amp; staining</subject><subject>Tumors</subject><subject>Ureteral Neoplasms - diagnosis</subject><subject>Ureteral Neoplasms - metabolism</subject><subject>Ureteral Neoplasms - pathology</subject><subject>Urinary Bladder Neoplasms - diagnosis</subject><subject>Urinary Bladder Neoplasms - metabolism</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urothelial carcinoma</subject><issn>0046-8177</issn><issn>1532-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkT2P1DAQhi0E4paFnwCyREOT3Iwd54MGoRMcSCdBAbXl2A7xKokXf5y0_x6fdqGguWqa531nNA8hrxFqBGyvD_Wc16NKc80AhxqaGpA9ITsUnFU9H9hTsgNo2qrHrrsiL2I8ACCKRjwnVxxBNP3Q7cj990XFVelT8s5cGzdNOVqag0-zXZxaqFZBu82v6j1VNLrt12Irt8XkUk7Ob9Sta9787GLyerar0yWjNkNXv1idFxVoTNmcqJ9oO9BysLNbii_Js0kt0b66zD35-fnTj5sv1d232683H-8qLaBNlUUuOHI-TZ3mBpRBpZoe-mZoWT-OFrUSXT9q5LrT4wgwDaNhE4AZ0GDP-Z68O_ceg_-dbUxydVHbZVGb9TlKxjhDxBZEQd_-hx58Dlu5rlAta9tGFHpPxJnSwccY7CSPwa0qnCSCfBAjD_IiRj6IkdDIIqbk3lza87ha8y_110QBPpwBW95x72yQUZdXaWtcsDpJ490jK_4AC86jzQ</recordid><startdate>201908</startdate><enddate>201908</enddate><creator>Perrino, Carmen M.</creator><creator>Eble, John</creator><creator>Kao, Chia-Sui</creator><creator>Whaley, Rumeal D.</creator><creator>Cheng, Liang</creator><creator>Idrees, Mohammad</creator><creator>Hashemi-Sadraei, Neda</creator><creator>Monn, M. Francesa</creator><creator>Kaimakliotis, Hristos Z.</creator><creator>Bandali, Elhaam</creator><creator>Grignon, David</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201908</creationdate><title>Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients</title><author>Perrino, Carmen M. ; Eble, John ; Kao, Chia-Sui ; Whaley, Rumeal D. ; Cheng, Liang ; Idrees, Mohammad ; Hashemi-Sadraei, Neda ; Monn, M. Francesa ; Kaimakliotis, Hristos Z. ; Bandali, Elhaam ; Grignon, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-e1353133ff7c3d0ad1aa480849628bbe1ca578bc13c7cbb00f9bd2f00d91d1833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Bladder</topic><topic>Bladder cancer</topic><topic>Breast cancer</topic><topic>Carcinoma, Transitional Cell - diagnosis</topic><topic>Carcinoma, Transitional Cell - metabolism</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Diffuse</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Keratin</topic><topic>Kidney Neoplasms - diagnosis</topic><topic>Kidney Neoplasms - metabolism</topic><topic>Kidney Neoplasms - pathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Morphology</topic><topic>Plasmacytoid</topic><topic>Retrospective Studies</topic><topic>Signet ring</topic><topic>Stains &amp; staining</topic><topic>Tumors</topic><topic>Ureteral Neoplasms - diagnosis</topic><topic>Ureteral Neoplasms - metabolism</topic><topic>Ureteral Neoplasms - pathology</topic><topic>Urinary Bladder Neoplasms - diagnosis</topic><topic>Urinary Bladder Neoplasms - metabolism</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urothelial carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perrino, Carmen M.</creatorcontrib><creatorcontrib>Eble, John</creatorcontrib><creatorcontrib>Kao, Chia-Sui</creatorcontrib><creatorcontrib>Whaley, Rumeal D.</creatorcontrib><creatorcontrib>Cheng, Liang</creatorcontrib><creatorcontrib>Idrees, Mohammad</creatorcontrib><creatorcontrib>Hashemi-Sadraei, Neda</creatorcontrib><creatorcontrib>Monn, M. Francesa</creatorcontrib><creatorcontrib>Kaimakliotis, Hristos Z.</creatorcontrib><creatorcontrib>Bandali, Elhaam</creatorcontrib><creatorcontrib>Grignon, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Human pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perrino, Carmen M.</au><au>Eble, John</au><au>Kao, Chia-Sui</au><au>Whaley, Rumeal D.</au><au>Cheng, Liang</au><au>Idrees, Mohammad</au><au>Hashemi-Sadraei, Neda</au><au>Monn, M. Francesa</au><au>Kaimakliotis, Hristos Z.</au><au>Bandali, Elhaam</au><au>Grignon, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients</atitle><jtitle>Human pathology</jtitle><addtitle>Hum Pathol</addtitle><date>2019-08</date><risdate>2019</risdate><volume>90</volume><spage>27</spage><epage>36</epage><pages>27-36</pages><issn>0046-8177</issn><eissn>1532-8392</eissn><abstract>Accurate diagnosis of plasmacytoid urothelial carcinoma (PUC) is important given its poor prognosis and frequent presentation at high stage. We aim to assess the clinicopathological features, molecular aberrations, and follow-up data in a series of PUC cases from a single tertiary cancer center. Seventy-two urinary bladder, ureteral, and renal pelvic specimens with urothelial carcinoma with plasmacytoid differentiation were identified. Immunohistochemical stains were performed on 48 cases. Among urinary bladder origin markers, GATA3 was most sensitive (96%). Breast carcinoma markers (estrogen receptor, mammaglobin) were usually negative, but progesterone receptor stained 1 case (4%). Neuroendocrine markers CD56 and TTF-1 were each positive in 1 case (4% and 4%, respectively). Gastrointestinal adenocarcinoma marker CDX2 was positive in 4 cases (15%), but nuclear β-catenin was negative in all cases. CD138 was positive in 83% and E-cadherin expression was lost in 57% of cases. Fluorescence in situ hybridization using the UroVysion Bladder Cancer Kit and FGFR3 mutational analysis using polymerase chain reaction were performed on 15 cases; deletion of chromosome 9p21 was common (60%), and FGFR3 mutations were detected in 60% of cases (5 cases had both deletion 9p21 and FGFR3 mutations). Cases were divided into 3 morphologic groups: classic (29%), desmoplastic (35%), and pleomorphic (36%). The 3 morphologic subtypes had distinct survival outcomes (P = .083), with median survival for all patients 18 being months versus 10 months for the desmoplastic group. •Urothelial carcinoma with plasmacytoid differentiation can be divided into 3 morphologic categories: (1) classic, (2) pleomorphic, and (3) desmoplastic.•Cases with plasmacytoid differentiation often present at a high stage, and within our dataset, cases assigned to the desmoplastic group had a worse outcome.•Urinary bladder origin immunohistochemical stains are sensitive for detecting the plasmacytoid variant.•Molecular aberrations present in conventional urothelial carcinoma are also present in the plasmacytoid variant.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31054897</pmid><doi>10.1016/j.humpath.2019.04.012</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0046-8177
ispartof Human pathology, 2019-08, Vol.90, p.27-36
issn 0046-8177
1532-8392
language eng
recordid cdi_proquest_miscellaneous_2232111605
source MEDLINE; ScienceDirect Freedom Collection (Elsevier)
subjects Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - metabolism
Bladder
Bladder cancer
Breast cancer
Carcinoma, Transitional Cell - diagnosis
Carcinoma, Transitional Cell - metabolism
Carcinoma, Transitional Cell - pathology
Diffuse
Female
Humans
Immunohistochemistry
Keratin
Kidney Neoplasms - diagnosis
Kidney Neoplasms - metabolism
Kidney Neoplasms - pathology
Male
Medical prognosis
Metastasis
Middle Aged
Morphology
Plasmacytoid
Retrospective Studies
Signet ring
Stains & staining
Tumors
Ureteral Neoplasms - diagnosis
Ureteral Neoplasms - metabolism
Ureteral Neoplasms - pathology
Urinary Bladder Neoplasms - diagnosis
Urinary Bladder Neoplasms - metabolism
Urinary Bladder Neoplasms - pathology
Urothelial carcinoma
title Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A09%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasmacytoid/diffuse%20urothelial%20carcinoma:%20a%20single-institution%20immunohistochemical%20and%20molecular%20study%20of%2069%20patients&rft.jtitle=Human%20pathology&rft.au=Perrino,%20Carmen%20M.&rft.date=2019-08&rft.volume=90&rft.spage=27&rft.epage=36&rft.pages=27-36&rft.issn=0046-8177&rft.eissn=1532-8392&rft_id=info:doi/10.1016/j.humpath.2019.04.012&rft_dat=%3Cproquest_cross%3E2262664522%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2262664522&rft_id=info:pmid/31054897&rft_els_id=S0046817719300772&rfr_iscdi=true